We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Calls for Further Studies for Intellipharmaceutics’ Rexista
FDA Calls for Further Studies for Intellipharmaceutics’ Rexista
The FDA sent Intellipharmaceutics a complete response letter for Rexista — an extended-release oxycodone tablet rejected in July by an FDA advisory committee — calling for additional studies of the drug’s abuse-deterrent properties.